New York State Common Retirement Fund boosted its stake in shares of CytomX Therapeutics, Inc. (NASDAQ:CTMX) by 18.6% during the 3rd quarter, HoldingsChannel.com reports. The firm owned 36,900 shares of the biotechnology company’s stock after acquiring an additional 5,800 shares during the period. New York State Common Retirement Fund’s holdings in CytomX Therapeutics were worth $670,000 as of its most recent SEC filing.

Other large investors have also added to or reduced their stakes in the company. Legal & General Group Plc boosted its position in shares of CytomX Therapeutics by 28.6% during the 2nd quarter. Legal & General Group Plc now owns 6,448 shares of the biotechnology company’s stock worth $101,000 after acquiring an additional 1,434 shares in the last quarter. Cubist Systematic Strategies LLC acquired a new position in shares of CytomX Therapeutics during the 2nd quarter worth about $174,000. Voya Investment Management LLC acquired a new position in shares of CytomX Therapeutics during the 2nd quarter worth about $203,000. Nationwide Fund Advisors boosted its position in shares of CytomX Therapeutics by 39.4% during the 2nd quarter. Nationwide Fund Advisors now owns 16,365 shares of the biotechnology company’s stock worth $254,000 after acquiring an additional 4,622 shares in the last quarter. Finally, Airain ltd acquired a new position in shares of CytomX Therapeutics during the 2nd quarter worth about $315,000. 63.13% of the stock is owned by institutional investors and hedge funds.

In related news, CEO Sean A. Mccarthy sold 14,342 shares of the company’s stock in a transaction dated Wednesday, November 1st. The stock was sold at an average price of $19.86, for a total value of $284,832.12. Following the completion of the sale, the chief executive officer now directly owns 18,587 shares of the company’s stock, valued at approximately $369,137.82. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, insider Sean A. Mccarthy sold 14,340 shares of the company’s stock in a transaction dated Friday, December 1st. The shares were sold at an average price of $20.60, for a total value of $295,404.00. The disclosure for this sale can be found here. Over the last three months, insiders sold 54,234 shares of company stock valued at $1,120,525. Insiders own 4.70% of the company’s stock.

Shares of CytomX Therapeutics, Inc. (NASDAQ:CTMX) opened at $24.87 on Friday. The stock has a market capitalization of $1,040.00 and a PE ratio of -15.84. CytomX Therapeutics, Inc. has a 1 year low of $10.64 and a 1 year high of $25.21.

Several research firms have recently issued reports on CTMX. BidaskClub raised CytomX Therapeutics from a “hold” rating to a “buy” rating in a research report on Friday, December 15th. Cowen reaffirmed an “outperform” rating on shares of CytomX Therapeutics in a research report on Thursday, October 5th. Oppenheimer reissued a “hold” rating on shares of CytomX Therapeutics in a research report on Wednesday, October 4th. Wedbush set a $37.00 target price on CytomX Therapeutics and gave the company a “buy” rating in a research report on Wednesday, October 4th. Finally, Cantor Fitzgerald assumed coverage on CytomX Therapeutics in a research report on Monday, October 23rd. They issued an “overweight” rating and a $35.00 target price for the company. Two research analysts have rated the stock with a sell rating, three have issued a hold rating and nine have issued a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus price target of $32.78.

ILLEGAL ACTIVITY WARNING: This piece of content was published by Watch List News and is the sole property of of Watch List News. If you are accessing this piece of content on another site, it was illegally copied and reposted in violation of US & international copyright & trademark laws. The correct version of this piece of content can be viewed at https://www.watchlistnews.com/new-york-state-common-retirement-fund-buys-5800-shares-of-cytomx-therapeutics-inc-ctmx/1797764.html.

About CytomX Therapeutics

CytomX Therapeutics, Inc is a clinical-stage, oncology-focused biopharmaceutical company. The Company uses its Probody technology platform to create cancer immunotherapies against clinically validated targets, as well as to develop cancer therapeutics against difficult-to-drug targets. Its pipeline is focused on the development of therapies in a set of modalities: Probody cancer immunotherapies, Probody drug conjugates, T-cell engaging Probody bispecifics and ProCAR-NK cell therapies.

Want to see what other hedge funds are holding CTMX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CytomX Therapeutics, Inc. (NASDAQ:CTMX).

Institutional Ownership by Quarter for CytomX Therapeutics (NASDAQ:CTMX)

Receive News & Ratings for CytomX Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytomX Therapeutics and related companies with Analyst Ratings Network's FREE daily email newsletter.